PRNewsWire
08 Jun 2026, 16:51 UTC · 15w ago
Verdict
Headline leans bearish. We score GRCE −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting Grace Therapeutics' New Drug Application for GTx-104.
More negative than 99% of claims this week
The FDA cited deficiencies in product packaging leachables, toxicology risk assessments, and contract manufacturing organization operations.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 95% of claims this week
The Schall Law Firm has launched a fraud investigation into Grace Therapeutics for potential violations of securities laws.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a fraud investigation following an FDA Complete Response Letter and a nearly 46% drop in share price.
More negative than 88% of ticker scores this week
The company is the subject of a fraud investigation by the Schall Law Firm.
More negative than 88% of ticker scores this week
The company is the subject of a fraud investigation by the Schall Law Firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−8.7%
Price agrees with the score
$2.10 vs $2.30 close before publication (Jun 5) · not market-adjusted
GRCE chart →